#Israel #Rehovot #Hyaluronic Acid #Enzymit #Cosun

Enzymit Achieves Breakthrough in Hyaluronic Acid Production

Enzymit, a pioneering synthetic biology firm, has announced a monumental achievement in the field of sustainable biomanufacturing. Together with Cosun, a leader in circular plant-based production, they have successfully produced high-purity hyaluronic acid (HA) using an innovative, enzyme-only, cell-free process at a pilot scale of 200 liters. This historic accomplishment marks the first instance of scalable, cell-free production of this valuable biopolymer, portraying a new direction in how biomanufacturing can evolve.

A New Era of Production

This groundbreaking pilot campaign yielded multi-kilogram quantities of hyaluronic acid, emphasizing superior efficiency and product consistency when compared to the traditional fermentation methods that have dominated the sector for years. Hyaluronic acid, renowned for its diverse applications including dermal fillers, wound healing, and drug delivery, has seen its market value soar to $9.43 billion in 2025, with projections estimating growth to $15.94 billion by 2035. This creates an urgency for high-quality, high-performance biomaterials, pointing to the relevance of Enzymit's advancements.

Enzymit’s production process stands out for its remarkable ability to control the size of hyaluronic acid during manufacturing. Unlike traditional methods, which rely on living organisms to produce compounds, Enzymit's cell-free approach utilizes enzyme-driven synthesis that allows manufacturers to define HA sizes ranging from approximately 10 kDa to around 4 MDa. This precise control over molecular size is achieved without the need to alter enzymes or organisms, representing a notable leap towards efficiency and customization in biomaterial production.

Marie Dobenesque, Chief Technology Officer at Cosun RDI, expressed pride in the collaboration, stating, "We are honored to have been part of Enzymit's journey, scaling their lab protocol to pilot production successfully utilizing our existing assets. Seeing this cell-free technology become industrially viable in such a short time is truly exciting."

Transforming the Future of Biomanufacturing

The technology harnessed by Enzymit combines AI-designed enzymes with a robust, cell-free system, enabling the synthesis of complex bioproducts without the typical limitations imposed by living cells. Gideon Lapidoth, CEO of Enzymit, articulated the significance of this achievement, remarking, "This isn't just a transformation in hyaluronic acid production; it’s a glimpse into a future where the creation of molecules is no longer confined to the capabilities of biological cells."

For Enzymit, this success carries the vision of revolutionizing green chemistry by turning towards a more sustainable, effective biomanufacturing paradigm. Founded with a mission to redefine the methodology of biomolecule production, the firm aims to create a new standard in bio-production that can compete with existing manufacturing technologies, all while emphasizing sustainability.

As they look ahead, Enzymit, backed by notable investors like Khosla and Grove Ventures, is dedicated to a future where any molecule can be produced on demand, ensuring both quality and sustainability.

About Enzymit and Cosun

Enzymit has quickly emerged as a leading force in the realm of synthetic biology through its innovative cell-free biomanufacturing processes, using enzyme-driven methods to offer alternatives to traditional cellular production. Cosun, an international agricultural cooperative, focuses on leveraging plant potentials to provide vital food ingredients while committing to sustainability and circular production practices. Together, they aim to redefine the possibilities within the biomanufacturing landscape, making significant strides toward a greener, more efficient future.

To learn more about Enzymit and their pioneering technologies, visit Enzymit’s official website. For insights on Cosun’s commitment to sustainable agriculture, explore Cosun's website.